Understand the source comparison
Peptide Mechanisms vs Standard AFib Therapies
Conventional AFib treatment targets symptom control: rate control drugs (beta-blockers, calcium channel blockers) slow AV nodal conduction; rhythm control drugs (flecainide, amiodarone, dofetilide) suppress ectopic beats and stabilise ion channels; anticoagula
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Conventional AFib treatment targets symptom control: rate control drugs (beta-blockers, calcium channel blockers) slow AV nodal conduction; rhythm control drugs (flecainide, amiodarone, dofetilide) suppress ectopic beats and stabilise ion channels; anticoagulation (warfarin, DOACs) reduces stroke risk. None of these reverse atrial remodelling. Catheter ablation physically isolates arrhythmogenic triggers. Usually pulmonary vein isolation. But does nothing to address the inflammatory, fibrotic, and oxidative processes that allow AFib to recur in 30–40% of patients within three years.
- Peptides operate at a different level. Thymosin beta-4 reduces the fibroblast activation and collagen accumulation that create slow conduction zones. BPC-157 normalises autonomic tone that would otherwise trigger ectopic firing from pulmonary vein sleeves. Epithalon improves mitochondrial efficiency, reducing the oxidative stress that damages ion channels and calcium handling proteins. These aren't competing therapies. They're complementary. Standard treatments suppress arrhythmia; peptides target the substrate.
- The limitation: peptide effects unfold over weeks to months, not minutes. A patient in acute AFib with rapid ventricular response needs immediate rate control. Peptides won't deliver that. But for patients in persistent AFib, or those with recurrent paroxysmal AFib despite ablation, peptides address the underlying tissue-level defects that standard therapies ignore. The challenge is that no large-scale randomised controlled trials in humans exist yet. The evidence base is animal models, in vitro studies, and mechanistic extrapolation.